Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Correction
First Online:
- 338 Downloads
1 Correction to: Clinical Pharmacokinetics https://doi.org/10.1007/s40262-018-0695-9
Section 1, para 2, lines 2-4 which previously read:
The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.
Should read:
The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), primarily by deoxycytidine kinase.
Section 2.4, para 3, lines 4-6 which previously read:
Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated by 5ʹ-nucleotidase to Cd-ATP [10, 11].
Should read:
Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated to Cd-ATP [10, 11].
Copyright information
© Springer Nature Switzerland AG 2018